Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Introduction (3 minutes)

Meet the experts who will be sharing their perspectives on key emerging therapies for HER2-positive metastatic breast cancer.
Adam M. Brufsky, MD, PhD
Program Director
Thomas Bachelot, MD, PhD
person default
Cristina Saura, MD, PhD
Released: September 11, 2020 Expiration: No longer available for credit

This program is divided into short segments that you can review from the activity landing page.

Related Content

Expert slides from Drs. Heather McArthur, Nadia Harbeck, and Komal Jhaveri, on HER2 testing, defining HER2-low status, and mastering the clinical use and safety profile of antibody-drug conjugates, from Clinical Care Options (CCO)

person default Nadia Harbeck, MD, PhD Komal Jhaveri, MD Heather McArthur, MD, MPH Released: December 8, 2022

Expert slides from Dr Melinda Telli on perioperative therapies for early triple-negative breast cancer (TNBC), from Clinical Care Options (CCO)

Melinda Telli, MD Released: December 7, 2022

Expert slides from Dr Tiffany Traina on perioperative therapies for high-risk HR+/HER2- early breast cancer, from Clinical Care Options (CCO)

Tiffany A. Traina, MD Released: December 7, 2022

Expert slides from Dr Joyce O’Shaughnessy on biomarkers defining patient subsets for early breast cancer, from Clinical Care Options (CCO)

Joyce O'Shaughnessy, MD Released: December 7, 2022

Video Chapters

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings